Blood · 2006 · 133 citations · 33 references
MedicineBiotechnologyOncologyAntibody EngineeringCancer ImmunologyVaccinologyCancer ImmunotherapyCancer VaccinesRecombinant Protein VaccinesVaccine DeliveryVaccine PlatformsCancer Vaccine ManufacturingFc Fusion Protein ExpressionFusion Protein VaccinesManufacturing Of Personalized VaccinesOncogenic Fusion ProteinsRecombinant Fusion ProteinsViral Fusion Proteins
The unique immunoglobulin (Ig) idiotype on the surface of each B-cell lymphoma represents an ideal tumor-specific antigen for use as a therapeutic vaccine. We have used an Escherichia coli-based, cell-free protein-expression system to produce a vaccine within hours of cloning the Ig genes from a B-cell tumor. We demonstrated that a fusion protein consisting of an idiotypic single chain Fv antibody fragment (scFv) linked to a cytokine (GM-CSF) or to an immunostimulatory peptide was an effective lymphoma vaccine. These vaccines elicited humoral immune responses against the native Ig protein displayed on the surface of a tumor and protected mice against tumor challenge with efficacy equal to that of the conventional Ig produced in a mammalian cell and chemically coupled to keyhole limpet hemocyanin. The cell-free E coli system offers a platform for rapidly generating individualized vaccines, thereby allowing much more efficient application in the clinic.
33
Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody
Richard Miller, David G. Maloney, Roger A. Warnke et al. · New England Journal of Medicine · 1982 · 990 citations
Medicine, Cancer Biology, Oncology +13
Cell‐free production and stable‐isotope labeling of milligram quantities of proteins
T. Kigawa, Takashi Yabuki, Yasuhiko Yoshida et al. · FEBS Letters · 1999 · 497 citations · Full text